Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo
Article
Article Title | Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo |
---|---|
ERA Journal ID | 16015 |
Article Category | Article |
Authors | Konstantopoulos, Nicky (Author), Molero, Juan C. (Author), McGee, Sean L. (Author), Spolding, Briana (Author), Connor, Tim (Author), de Vries, Melissa (Author), Wanyonyi, Stephen (Author), Fahey, Richard (Author), Morrison, Shona (Author), Swinton, Courtney (Author), Jones, Sharon (Author), Cooper, Adrian (Author), Garcia-Guerra, Lucia (Author), Foletta, Victoria C. (Author), Krippner, Guy (Author), Andrikopoulos, Sofianos (Author) and Walder, Ken R. (Author) |
Journal Title | Diabetes |
Journal Citation | 61 (8), pp. 2146-2154 |
Number of Pages | 9 |
Year | 2012 |
Place of Publication | United States |
ISSN | 0012-1797 |
1939-327X | |
Digital Object Identifier (DOI) | https://doi.org/10.2337/db11-0578 |
Web Address (URL) | http://diabetes.diabetesjournals.org/content/diabetes/61/8/2146.full.pdf |
Abstract | We previously used Gene Expression Signature technology to identify methazolarnide (MTZ) and related compounds with insulin sensitizing activity in vitro. The effects of these compounds were investigated in diabetic db/db mice, insulin-resistant diet-induced obese (DIO) mice, and rats with streptozotocin (STZ)-induced diabetes. MTZ reduced fasting blood glucose and HbA(1c) levels in db/db mice, improved glucose tolerance in DIO mice, and enhanced the glucose-lowering effects of exogenous insulin administration in rats with STZ-induced diabetes. Hyperinsulinentic-euglycemic clamps in DIO mice revealed that MTZ increased glucose infusion rate and suppressed endogenous glucose production. Whole-body or cellular oxygen consumption rate was not altered, suggesting MTZ may inhibit glucose production by different mechanism(s) to metformin. In support of this, MTZ enhanced the glucose-lowering effects of metformin in db/db mice. MTZ is known to be a carbonic anhydrase inhibitor (CM); however, CAIs acetazolamide, ethoxyzolamide, dichlorphenamide, chlorthalidone, and fmosemide were not effective in vivo. Our results demonstrate that MTZ acts as an insulin sensitizer that suppresses hepatic glucose production in vivo. The antidiabetic effect of MTZ does not appear to be a function of its known activity as a CM. The additive glucose-lowering effect of MTZ together with metformin highlights the potential utility for the management of type 2 diabetes. |
Keywords | carbonic-anhydrase inhibition; gene-expression signature; activated protein-kinase; metformin; gluconeogenesis; |
ANZSRC Field of Research 2020 | 321406. Pharmacogenomics |
321401. Basic pharmacology | |
Public Notes | Files associated with this item cannot be displayed due to copyright restrictions. |
Byline Affiliations | Deakin University |
Verva Pharmaceuticals, Australia | |
University of Melbourne | |
Institution of Origin | University of Southern Queensland |
https://research.usq.edu.au/item/q3x1v/methazolamide-is-a-new-hepatic-insulin-sensitizer-that-lowers-blood-glucose-in-vivo
1692
total views9
total downloads0
views this month0
downloads this month